CVS Health has declined to include Gilead’s new $28,000 HIV drug, Yeztugo, in its plans, citing regulatory and cost concerns, despite coverage by U.S. agencies and some states. Activists called the move a setback, though talks with Gilead continue. Separately, CVS Caremark was ordered to pay $289.9 million in a Medicare fraud case. Retail sentiment remains bullish.